inotuzumab ozogamicin,blinatumomab
pfizer,amgen,ucb pharmaceuticals
['leusm', 'inotuzumab']
congress #eha2023 | for 's second talk he presents a phase ii trial of mini-hyper-cvd +inotuzumab with blinatumumab consolidation. n=125. 91 pts responded (cr, 63%). the orr= 95 in salvage 1, 59% in salvage 2, &amp; 57% in salvage 3+. #leusm #allsm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm